News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
January, 2025
January 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Carmine Valenza: The Role of Germline BRCA Mutation in PARP Inhibitors-Related Hematologic Adverse Events
Carmine Valenza/X
Dec 5, 2024, 07:25

Carmine Valenza: The Role of Germline BRCA Mutation in PARP Inhibitors-Related Hematologic Adverse Events

Carmine Valenza, Medical Oncology Resident at the European Institute of Oncology, shared a post on X:

“Happy to share our last paper on the role of germline BRCA mutation in PARP inhibitors-related hematologic adverse events.

 No differences between carriers vs. non-carriers.

Thanks to all the coauthors, Eleonora Nicolò, Dario Trapani, Luca Boscolo Bielo, Lorenzo Guidi, G Curigliano.”

Title: Germline BRCA pathogenic variants and hematologic adverse events in patients with ovarian carcinoma receiving PARP inhibitors: a retrospective cohort study 

Authors: Carmine Valenza, Eleonora Nicolò, Marta Mongillo, Dario Trapani, Jalissa Katrini, Laura Boldrini, Luca Boscolo Bielo, Grazia Castellano, Lorenzo Guidi, Gloria Pellizzari, Jacopo Villa, Silvia Derio, Mariateresa Lapresa, Federica Gigli, Gabriella Parma, Emanuela Omodeo Salè, Enrico Derenzini, Giuseppe Curigliano and Nicoletta Colombo

Carmine Valenza

More posts featuring Carmine Valenza.

BRCA mutation cancer Carmine Valenza Dario Trapani Eleonora Nicolò Emanuela Omodeo Salè Enrico Derenzini germline Giuseppe Curigliano Gloria Pellizzari Grazia Castellano hematologic adverse events IEO Jacopo Villa Jalissa Katrini Laura Boldrini Lorenzo Guidi Luca Boscolo Bielo Mariateresa Lapresa Marta Mongillo Nicoletta Colombo OncoDaily Oncology PARP inhibitors Silvia Derio
Special Coverage
Blog
Jan 20, 2025, 04:32
Bevacizumab and carboplatin-pemetrexed chemotherapy with/out atezolizumab for advanced pleural mesothelioma
Blog
Jan 20, 2025, 04:29
Katsuaki Maehara: Lung EGFR mutations catalog
Opinion
Jan 20, 2025, 04:25
Elisabetta Bonzano: The identification and validation of patient-specific vulnerabilities
Blog
Jan 20, 2025, 04:21
Robin Zon: Behind every diagnosis, test, approval/ disapproval and outcome is a patient and their family
Insight
Jan 20, 2025, 04:14
Laura Bukavina discusses a paper on BCG treatment for patients with urothelial carcinoma of the prostatic urethra
Insight
Jan 20, 2025, 04:00
FDA approved datopotamab deruxtecan-dlnk for unresectable or metastatic, HR-positive, HER2-negative breast cancer
Career
Jan 20, 2025, 03:10
Lawrence “Larry” Deist Appointed to Board of Directors at Rally Foundation for Childhood Cancer Research
Blog
Jan 20, 2025, 02:54
Drew Moghanaki: A new medical oncology position at the VA Medical Center in Long Beach
Science
Jan 20, 2025, 02:44
Assessment of fitness for bleomycin use and management of bleomycin pulmonary toxicity in patients with classical HL
Science
Jan 20, 2025, 02:16
Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer
Blog
Jan 20, 2025, 02:14
Akriti Jain: Grateful to present at Cleveland Clinic ASH review
Career
Jan 19, 2025, 23:12
Kimryn Rathmell Steps Down as NCI Director, Concluding a Pivotal Leadership Era